Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH2 | P48735 | 6/20 | 0.47 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | APP | P05067 | 3/20 | 0.46 |
| ▸ | AURKA | O14965 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11936715 | 0.89 | CDK1 (0.39) | APPCYP1A2CYP3A4CYP2C19ABCG2 | |
| SCHEMBL11936714 | 0.82 | SLC2A1 (0.44) | CYP1A2CYP3A4CYP2C19ABCG2 | |
| SCHEMBL11936712 | 0.81 | CYP2C9 (0.39) | MAPTCYP1A2CYP3A4CYP2C19ABCG2 | |
| SCHEMBL11936717 | 0.81 | AR (0.49) | CYP1A2CYP3A4CYP2C19ABCG2 | |
| SCHEMBL11936713 | 0.79 | CDK2 (0.42) | MAPTLMNAMAPK1CYP1A2CYP3A4 | |
| SCHEMBL11936687 | 0.77 | CYP2C9 (0.56) | AURKACYP1A2CYP3A4CYP2C19ABCG2 | |
| SCHEMBL11936719 | 0.76 | KCNH2 (0.38) | CYP1A2CYP3A4CYP2C19ABCG2 | |
| SCHEMBL11936697 | 0.76 | NPC1 (0.46) | MAPTAURKAKDM4ECYP1A2CYP3A4 | |
| SCHEMBL11936694 | 0.75 | CDK2 (0.51) | — | |
| SCHEMBL11936698 | 0.75 | CDK2 (0.44) | KDM4ECYP1A2CYP3A4CYP2C19ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354532-B2 | Pyrrolo [2,3-D] pyrimidines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV | ARDEA BIOSCIENCES, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354532-B2 | Pyrrolo [2,3-D] pyrimidines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV | ARDEA BIOSCIENCES, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120226037-A1 | PYRROLO [2,3-D] PYRIMIDINES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF HIV | ARDEA BIOSCIENCES, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120226037-A1 | PYRROLO [2,3-D] PYRIMIDINES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF HIV | ARDEA BIOSCIENCES, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-8227601-B2 | Diaryl-purines, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitor for treatment of HIV | ARDEA BIOSCIENCES, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227601-B2 | Diaryl-purines, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitor for treatment of HIV | ARDEA BIOSCIENCES, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20090124802-A1 | Diaryl-purines, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitor for treatment of hiv | INTRABIOTICS PHARMACEUTICALS, INC. | 2009-05-14 | — | — | US | disclosed |
| US-20090124802-A1 | Diaryl-purines, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitor for treatment of hiv | INTRABIOTICS PHARMACEUTICALS, INC. | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120226037-A1 | PYRROLO [2,3-D] PYRIMIDINES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF HIV | TYMP, TPMT, PNP | IDH2 1036/4885RAPGEF4 3044/4885MAPT 1645/4885 |
| US-20090124802-A1 | Diaryl-purines, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitor for treatment of hiv | PNP, TPMT, DUT | IDH2 1021/4885RAPGEF4 2194/4885MAPT 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.